ICON Launches Accellacare a Global Clinical Research Network Focused on Increasing Patient Recruitment With a Patient Centric...
03 Setembro 2020 - 5:30AM
Business Wire
Enhances ICON’s ability to offer customers
integrated solutions of patient assessments at site and in-home for
decentralised trials
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
drug and device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries and
government and public health organisations, today announced that it
is launching Accellacare a global clinical research network
offering patients easier and faster access to innovative treatments
and offering customers the option to deploy decentralised trials.
The site network includes previously acquired PMG Research in the
US and MeDiNova Research in EMEA.
Accellacare’s patient centric approach focusing on enhancing the
patient experience and providing patient assessments either at
site, or at home as part of integrated operations with Symphony
Clinical Research, the leading global provider of at-home care and
nursing for clinical trials owned by ICON, is leading to higher
recruitment and retention rates. Accellacare is also achieving
faster study start-up for its customers through efficiencies gained
in central process management including budget and contracting,
which can otherwise be a source of delay. This combined with a
finely tuned feasibility approach ensures that the network can
identify and recruit more patients to studies, in a wide range of
therapeutic areas, in a shorter time frame
Dr. Steve Cutler, Chief Executive Officer, ICON plc, said:
“Accellacare is an important part of our integrated patient, site and data strategy,
helping us to improve patient recruitment and retention.
Accellacare is committed to delivering on the promise of patient
centricity in clinical research which is bringing benefits to both
patients and sponsors. It is also providing investigators with
innovative treatments for their patients with a quality-focused
clinical research infrastructure supported by experienced
professionals globally.”
About Accellacare Accellacare is a global clinical
research network increasing patient recruitment and retention with
a patient centric approach. The Accellacare feasibility and central
process management enables faster study start-up and its dedicated
patient engagement team drives identification and recruitment of
suitable patients, using an extensive database of patients and
targeted campaigns, resulting in higher recruitment levels per
site. Accellacare extends across the globe with 77 active research
sites in seven countries with particular expertise in 12
therapeutic areas. It has relationships with 275 Principal
Investigators connecting it to 8 million+ patients.
Further information is available at www.accellacare.com
About ICON plc ICON plc is a global provider of
outsourced drug and device development and commercialisation
services to pharmaceutical, biotechnology, medical device and
government and public health organisations. The company specialises
in the strategic development, management and analysis of programs
that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland,
ICON currently operates from 94 locations in 40 countries and has
approximately 15,150 employees as of June 30, 2020.
Further information is available at www.iconplc.com/sites
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005029/en/
ICON Media Contact Gareth Arnold Weber Shandwick
Telephone: (+44) 07944 688281 GArnold@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024